-
Mashup Score: 0Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2 | Journal of Clinical Oncology - 7 month(s) ago
PURPOSEIt is uncertain whether, and to what extent, hormonal contraceptives increase breast cancer (BC) risk for germline BRCA1 or BRCA2 mutation carriers.METHODSUsing pooled observational data from four prospective cohort studies, associations between …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1The Effect on Travel Distance of a Statewide Regionalization Policy for Initial Breast Cancer Surgery | Journal of Clinical Oncology - 7 month(s) ago
PURPOSEReimbursement strategies to regionalize care can be effective for improving patient outcomes but may adversely affect access to care. We sought to determine the effect on travel distance for surgical treatment of a 2009 New York State (NYS) policy …Regionalizing breast cancer surgery for Medicaid patients improved survival with minimal effect on access.
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
The Effect on Travel Distance of a Statewide Regionalization Policy for Initial #BreastCancer Surgery: https://t.co/4Xmu8KccJP #bcsm
-
-
Mashup Score: 3Cancer of the Breast (Female) - Cancer Stat Facts - 7 month(s) ago
Female Breast Cancer statistics
Source: seer.cancer.govCategories: General Medicine News, Onc News and JournalsTweet-
The rate of new #BreastCancer cases is slightly higher than average for Non-Hispanic White and Non-Hispanic Black women. There was an average of 127 cases per 100,000 women between 2016-2020. Visit our Cancer Stat Facts sheet to learn more: https://t.co/wUKAVg2gqh #BCSM https://t.co/FuMRTMOSse
-
-
Mashup Score: 2Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer | JCO Oncology Practice - 7 month(s) ago
PURPOSESacituzumab govitecan (SG) is approved for the treatment of metastatic triple-negative breast cancer (mTNBC). We report the real-world clinical effectiveness and toxicity data of SG in patients with mTNBC.METHODSA multi-institution retrospective …Our multi-institutional study demonstrates that sacituzumab govitecan is effective in heavily pretreated patients with metastatic triple-negative breast cancer, maintaining clinical efficacy with manageable toxicity. Additionally, we observed that …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative #BreastCancer: https://t.co/FVf4e1WFee #bcsm @royaryam @gandhi_shipra
-
-
Mashup Score: 21
PURPOSEThe global, phase 3, open-label, randomized TROPION-Breast01 study assessed the trophoblast cell surface antigen 2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) versus investigator’s choice of chemotherapy (ICC) in hormone …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative #BreastCancer: Primary Results From TROPION-Breast01 https://t.co/6UwKRrAqll #bcsm
-
-
Mashup Score: 1Risk-Reducing Mastectomy Incurs Psychological Symptoms in Postsurgical Period - Oncology Nurse Advisor - 7 month(s) ago
Women at high-risk for breast cancer experienced immediate psychological effects before and after surgical procedure to reduce their risk of disease.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Comprehensive psychological interventions before and after surgery could help address the psychological consequences experienced by patients with #breastCancer who undergo risk-reducing mastectomy. Published in @OncologyAdvance. https://t.co/UfjPrGp5QP #BCSM
-
-
Mashup Score: 0
This clinical insights article is derived from recommendations in Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. This document is based on an ASCO Guideline and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This article does not purport to suggest any particular
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early #BreastCancer—CDK4/6 Inhibitors: ASCO Rapid Guideline Update Clinical Insights https://t.co/ZxeBzBeuA8 #bcsm
-
-
Mashup Score: 1
PURPOSEAs metastatic breast cancer (mBC) treatment evolves, there is a need to understand how clinical meaningfulness, or a meaningful change in a patient’s daily life, and clinically meaningful outcomes inform patient-centered care. Partnering with key …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Investigating the Salience of Clinical Meaningfulness and Clinically Meaningful Outcomes in Metastatic #BreastCancer Care Delivery: https://t.co/dSK8jxpblw #bcsm
-
-
Mashup Score: 0Dr Brufsky on the Unique Design of the Allogeneic SV-BR-1-GM Vaccine in Metastatic Breast Cancer - 8 month(s) ago
Adam M. Brufsky, MD, PhD, FACP, discusses the unique design of the allogeneic GM-CSF–secreting breast cancer vaccine SV-BR-1-GM.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
🔔 Tune in to hear @breastoncdoc, of @UPMCHillmanCC, as he discusses the unique design of the allogeneic GM-CSF–secreting #BreastCancer vaccine SV-BR-1-GM. #bcsm https://t.co/X5pOOIa4Cg
-
-
Mashup Score: 0Higher sTIL Levels Linked to Better Outcomes in Stage I TNBC - Oncology Nurse Advisor - 8 month(s) ago
Patients with stage I TNBC who had higher sTIL levels had “excellent” 10-year breast cancer-specific survival, according to researchers.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Patients with stage I triple-negative #breastcancer who have higher levels of sTILs can have “excellent” 10-year breast cancer-specific survival without neoadjuvant or adjuvant chemotherapy, according to researchers. From @JAMAOnc and @cancertheradv. https://t.co/HyKtEvSVKH #BCSM
-
Hormonal Contraception and #BreastCancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2: https://t.co/KGn0CzTPmY #bcsm